|
 |
CancidasThis page contains recent news articles, when available, and an overview of Cancidas but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Cancidas (when available) Caspofungin is an antifungal drug, and belongs to a new class termed the echinocandins. It is used to treat Aspergillus and Candida infection, and works by inhibiting cell wall synthesis. Antifungals in the echinocandin class inhibit the synthesis of glucan in the cell wall, probably via the enzyme 1,3-beta glucan synthase. There is a potential for resistance development to occur, however in vitro resistance development to Caspofungin by Aspergillus species has not been studied. For the treatment of Esophageal Candidiasis and Invasive Aspergillosis in patients who are refractory to or intolerant of other therapies Mechanism Of Action: Caspofungin inhibits the synthesis of b (1,3)-D-glucan, an essential component of the cell wall of Aspergillus species and Candida species. b (1,3)-D-glucan is not present in mammalian cells. The primary target is Beta-(1,3)-glucan synthase. News Articles on Caspofungin Merck Announces Third-Quarter 2009 Financial Results - Oct 22, 2009 Inc.) $2.7 to $3.0 billion Other reported products* $6.4 to $6.8 billion * Other reported products is comprised of: ARCOXIA, CANCIDAS, COSOPT, CRIXIVAN, ... Reuters EU agency backs Merck's Cancidas for children - Sep 26, 2008 LONDON (Reuters) - The European Medicines Agency has recommended Merck & Co's (MRK.N) Cancidas for use in children with severe fungal infections, ... Reuters Drug Trials With a Dose of Doubt -- latimes.com - Jul 16, 2006 In its first five years on the US market, Cancidas would generate $859 million in sales for Merck. US law generally prohibits a federal employee from ... Los Angeles Times FDA Approves Expanded Label For CANCIDAS(R) As The 1st And Only … - Aug 8, 2008 Merck & Co., Inc. announced that the US Food and Drug Administration (FDA) has approved an expanded label for CANCIDAS®, which makes it the first and only ... Medical News Today - Medical News Today (press release) Cancidas As Empirical Therapy Of Suspected Invasive Fungal Infections... - Sep 20, 2007 CANCIDAS® (caspofungin acetate) had a safety and efficacy profile generally similar to AmBisomeTM (liposomal amphotericin B or L-AmB) in a clinical study ... Medical News Today - Medical News Today (press release) Merck re-enters Indian market - Jul 23, 2005 This will be followed by the launch of Invanz (a second generation beta-lactam anti-biotic) and Cancidas (an anti-fungal) and two vaccines — Pneumovax ... Hindu Interim Results from a New Trial of CANCIDAS(R) (caspofungin acetate)... - Oct 5, 2007 SAN DIEGO -- CANCIDAS([R]) (caspofungin acetate), given once daily, was evaluated as a treatment for patients three months to 17 years of age with ... Free with registration - Business Wire - AccessMyLibrary.com MSD India launches CANCIDAS IV anti-fungal drug in India - Sep 1, 2006 MSD India, a wholly owned subsidiary of Merck & Co. Inc., today launched their latest anti fungal drug, Cancidas IV (caspofugin acetate 50mg/ 70mg), ... pharmabiz.com Study Presented on Use of CANCIDAS(R) (caspofungin acetate) as … - Sep 17, 2007 CHICAGO -- CANCIDAS([R]) (caspofungin acetate) had a safety and efficacy profile generally similar to AmBisome([R]) (liposomal amphotericin B or L-AmB) in a ... Free with registration - Business Wire - AccessMyLibrary.com … Results From A New Trial Of CANCIDAS® (caspofungin Acetate) In … - Oct 8, 2007 CANCIDAS® (caspofungin acetate), given once daily, was evaluated as a treatment for patients three months to 17 years of age with documented or suspected ... Medical News Today - Medical News Today (press release) Schering-Plough's new anti-fungal gains EMEA approval - Aug 1, 2005 Noxafil will compete with Merck Sharp & Dohme's Cancidas (caspofungin) and ... Vfend is in the same triazole as Noxafil whereas Cancidas is a peptide ... Pharmafocus Noxafil close to approval for invasive fungal infections - Sep 25, 2006 The drug is competing with Merck Sharp & Dohme's Cancidas (caspofungin) and ... Vfend is in the same triazole class as Noxafil, whereas Cancidas is in the ... Pharmafocus Cancidas. - Oct 1, 2008 Caspofungin (Cancidas, Merck) was approved for use in pediatric patients aged 3 months to 17 years as empiric therapy for presumed fungal infections in ... $9.94 - Formulary - Alacra Store Merck & Co's Cancidas comparable to AmBisome in IFI. - Oct 1, 2007 US drug major Merck & Co's Cancidas (caspofungin acetate) demonstrated a safety and efficacy profile generally similar to Gilead Sciences' antifungal agent ... $4.95 - Pharma Marketletter - ECNext Merck claims positive HIV drug data - Aug 8, 2008 Meanwhile, the drugs giant has just revealed that the US Food and Drug Administration has approved an expanded label for Cancidas. ... Hays Pharma 商å“?回檔轉進科技生醫股 - Aug 10, 2008 ...油價回檔激勵零售å?Šæ±½è»Šç‰æ¶ˆè²»è€?久財類股上漲1.75%ï¼Œé»˜å…‹è—¥å» æ–°è—¥CANCIDASç?²å¾—FDAå?Œæ„? 為治療å°?兒科真è?Œæ„ŸæŸ“的首è¦?ç”¨è—¥ï¼Œç”ŸæŠ€å¤§å» å?‰åˆ©å¾·ç§‘旗下愛滋病藥物Truvada被è‰å¯¦ ... è?¯å?ˆæ–°è?žç¶² How Many Birthdays Can You Have - Mar 30, 2007 The only medicine that can save Katya is Cancidas, one bottle a day. ... Yet, when expensive Cancidas only can literally save life, doctors are at a loss: ... Kommersant MSD India launches new anti-fungal drug - Sep 30, 2006 Cancidas IV is the first to be approved in a new class of anti-fungals. "Cancidas has set a new gold standard in the anti-fungal drugs domain with beaming ... Express Pharma Press Release: Echinocandins Show Growth Among All Antifungal … - Oct 30, 2008 Merck's Cancidas and Astellas's Mycamine Cut Prices, According To New Data from ... "Cancidas currently enjoys the largest share of courses within the ... Pay-Per-View - PR Newswire - HighBeam Research The Nation; NIH Audit Criticizes Scientist's Dealings; A researcher … - Sep 10, 2006 The new documents show that when Merck paid Walsh a $2000 fee in September 2000, it was to discuss the company's new antifungal drug, Cancidas, ... Pay-Per-View - Los Angeles Times - ProQuest Archiver 'Heroes of Chemistry' honored for medical, green chemistry … - Aug 28, 2006 Merck & Co., Inc., Whitehouse Station, NJ, developed CANCIDAS® to treat serious ... CANCIDAS® is the first of a new class of antifungal agents to reach ... eurekalert.org Honors For Medical, Green Chemistry Breakthroughs Go To "Heroes Of … - Aug 30, 2006 Merck & Co., Inc., Whitehouse Station, NJ, developed CANCIDAS to treat serious ... CANCIDAS is the first of a new class of antifungal agents to reach ... Medical News Today - Medical News Today (press release) Article: 'F&M' pigs get all clear.(News) - The Mirror (London,... - Jan 26, 2005 Article: Treatment with Cancidas(TM) Resulted in Favorable Response for . ... The study results showed Cancidas had in vitro activity across the spectrum of ... Pay-Per-View - The Mirror - HighBeam Research Article: FDA Panel Frowns on Vioxx Successor - AP Online | HighBeam … - Apr 12, 2007 Manufacturer Merck & Co. gave Cancidas, known chemically ... t tolerate other treatments, ... Merck said Cancidas will be available in 10 ... ... Pay-Per-View - Associated Press/AP Online - HighBeam Research … FDA approval for an expanded label for Cancidas, which makes it... - Sep 15, 2008 ...(www.merck.com) received FDA approval for an expanded label for Cancidas, which makes it the first and only echinocandin therapy approved in the United ... $9.94 - Drug Topics - Alacra Store Recommendation Against Vioxx Successor | Article from AP Online | … - Apr 12, 2007 Manufacturer Merck & Co. gave Cancidas, known chemically ... t tolerate other treatments, ... Merck said Cancidas will be available in 10 ... ... Pay-Per-View - Associated Press/AP Online - HighBeam Research Awards; Scientists honored for medical, green chemistry breakthroughs - Sep 19, 2006 Merck & Co., Inc., Whitehouse Station, NJ, developed CANCIDAS to treat serious fungal ... CANCIDAS is the first of a new class of antifungal agents to reach ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones FDA Panel Frowns on Vioxx Successor | Article from AP Online | … - Apr 12, 2007 Manufacturer Merck & Co. gave Cancidas, known chemically ... t tolerate other treatments, ... Merck said Cancidas will be available in 10 ... ... Pay-Per-View - Associated Press/AP Online - HighBeam Research Article: FDA Panel Frowns on Vioxx Successor - AP Online | HighBeam … - Apr 13, 2007 Manufacturer Merck & Co. gave Cancidas, known chemically ... t tolerate other treatments, ... Merck said Cancidas will be available in 10 ... ... Pay-Per-View - Associated Press/AP Online - HighBeam Research FDA Panel Frowns on Vioxx Successor | Article from AP Online | … - Apr 12, 2007 Manufacturer Merck & Co. gave Cancidas, known chemically ... t tolerate other treatments, ... Merck said Cancidas will be available in 10 ... ... Pay-Per-View - Associated Press/AP Online - HighBeam Research Mycamine - bolstering the antifungal armory - Mar 23, 2005 Similar to Cancidas, Mycamine is only available in an IV formulation and is likely to be priced at a premium to the older antifungals such as Diflucan and ... Pay-Per-View - Datamonitor News and Comment - Factiva, from Dow Jones Article: FDA Panel Frowns on Vioxx Successor - AP Online | HighBeam … - Apr 12, 2007 Manufacturer Merck & Co. gave Cancidas, known chemically ... t tolerate other treatments, ... Merck said Cancidas will be available in 10 ... ... Pay-Per-View - Associated Press/AP Online - HighBeam Research Recommendation Against Vioxx Successor | Article from AP Online | … - Apr 12, 2007 Manufacturer Merck & Co. gave Cancidas, known chemically ... t tolerate other treatments, ... Merck said Cancidas will be available in 10 ... ... Pay-Per-View - Associated Press/AP Online - HighBeam Research FDA Panel Frowns on Vioxx Successor | Article from AP Online | … - Apr 12, 2007 Manufacturer Merck & Co. gave Cancidas, known chemically ... t tolerate other treatments, ... Merck said Cancidas will be available in 10 ... ... Pay-Per-View - Associated Press/AP Online - HighBeam Research Bipartisan Group Of Congressional Lawmakers Asks NIH To Investigate … - Aug 14, 2006 In addition, Merck in 2001 called Walsh as a witness as part of a presentation of the results of the Cancidas trial to an FDA advisory committee. ... Medical News Today - Medical News Today (press release) FDA Panel Frowns on Vioxx Successor | Article from AP Online | … - Apr 12, 2007 Manufacturer Merck & Co. gave Cancidas, known chemically ... t tolerate other treatments, ... Merck said Cancidas will be available in 10 ... ... Pay-Per-View - Associated Press/AP Online - HighBeam Research Intensified Competition in Severe Fungal Infections Drug Market. |... - Nov 1, 2008 Following the recent launches of several next-generation azoles (such as Vfend and Noxafil) and echinocandins (such as Cancidas, Mycamine and Eraxis), ... Pay-Per-View - BIOTECH Patent News - HighBeam Research Press Release: Uptake of Next-Generation Antifungals Has Intensified ... - Nov 19, 2008 Following the recent launches of several next-generation azoles (such as Vfend and Noxafil) and echinocandins (such as Cancidas, Mycamine and Eraxis), ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Total Worldwide Market for Antibiotics and Antifungals... - Dec 12, 2006 One new triazole ... and one peptide antifungal (Cancidas) have ... and three peptide antifungals competing on the ... novel targets for antifungal therapy ... Pay-Per-View - M2 Presswire - HighBeam Research Merck, Indian firm team up - May 13, 2008 Merck currently has one antifungal drug on the market, Cancidas, but is one of the top makers of vaccines to prevent infectious diseases. ... Boston Globe Merck Announces First-Quarter 2005 Earnings Per Share -EPS- of 62 … - Apr 21, 2005 ...migraine, arthritis and pain. An important contributor to the growth of sales of Merck's other promoted medicines was CANCIDAS, with worldwide. Free with registration - Business Wire - AccessMyLibrary.com FDA Commissioner Hearings Begin: Nominee Takes Heat from Both … - Aug 2, 2006 Ambisome and Cancidasâ€?, said McClusky. “More troubling the FDA seems willing to ignore the serious threat to women's health posed by RU-486.â€? ... Lifesite סל הברי×?ות הב×?: 181 תרופות חדשות - Jan 31, 2005 ...cancidas - טיפול בזיהומי×? פטרייתיי×?, lexiva - טיפול ×œ× ×©×?×™ ×?יידס, emtriva - טיפול ×œ× ×©×?×™ ×?יידס, ... NRG מעריב IOM head says stronger FDA is needed.(NEWS) | Article from Medical … - May 1, 2008 Article: Cancidas[R].(Food and Drug Administration ... Medical Marketing & Media; March 1, 2001 ; 583 words ...The Anriviral Advisory Committee of the Food ... Pay-Per-View - Medical Marketing & Media - HighBeam Research KAI Pharmaceuticals Announces Appointment of Chief Medical Officer;... - Aug 31, 2005 Dr. Bell began his career at Merck as Program Manager in Merck Research Laboratories supporting the Cancidas(R) and Arcoxia(R) programs. ... RedOrbit MSD Chibret inaugure une nouvelle production à ... - Chimie - Nov 26, 2007 Une décision prise par le groupe Merck&Co de transférer sa production en Auvergne du Cancidas, un antifongique, actuellement produit chez Catalent, ... L'Usine Nouvelle 'We are on the lookout for partnerships' - Oct 6, 2005 The drugs include Invanz (a new generation antibiotic used to treat gram positive and negative bacteria), Cancidas (anti-fungal drug), Pneumovax (pneumonia ... expresspharmapulse.com Stronger warnings ordered for 4 arthritis medications.(Front) |... - Sep 5, 2008 The government approved a new drug called Cancidas on Monday for immune-weakened patients suffering an often fatal fungal infection. ... Pay-Per-View - Virginian-Pilot - HighBeam Research Micafungin approval strengthens antifungal armamentarium.(Infectious ... - May 1, 2005 The echinocandin class also includes caspofungin (Cancidas), approved in 2001. Two more drugs in this class, anidulafungin and aminocandin, ... Free with registration - Family Practice News - AccessMyLibrary.com There's a new option for treating systemic fungal infections.(Rx... - Apr 18, 2005 ..."Until the approval of caspofungin (Cancidas, Merck) and voriconazole (Vfend, Pfizer), the treatment options for systemic fungal infections were very ... Free with registration - Drug Topics - AccessMyLibrary.com Merck to roll out money-spinning drugs soon - Mar 19, 2007 MSD, which made a re-entry to the Indian market in 2005 (after a gap of 16 years), is currently having just three products - Cancidas, Zienam and Aggrastat ... Business Standard 抗真è?Œè?¯ç‰©å¸‚åœºç«žäº‰åŠ å‰§ - Oct 31, 2006 ...å…¨ç?ƒç¬¬ä¸€ä¸ªé—®ä¸–的棘ç?ƒç™½ç´ 类抗真è?Œè?¯ä¸ºç¾Žå›½é»˜å…‹å…¬å?¸çš„å?¡æ³ŠèŠ¬å‡€(caspofungin,cancidas, 科赛斯),于2001å¹´1月首次上市,ç›®å‰?已在70多个国家被广泛使用。 ... æ?œç‹? Echinocandins offer antifungal therapy with low toxicity, few drug... - May 15, 2005 The echinocandin caspofungin (Cancidas) has "no significant interaction" with cytochrome P-450 (CYP450) metabolism or P-glycoprotein, according to product ... Free with registration - Internal Medicine News - AccessMyLibrary.com Schering-Plough: New Fungicide Gets US Approval - Sep 20, 2006 Merck's Cancidas (caspofungin), the first drug in this class, was launched in 2001 and now dominates the market for systemic antifungals, achieving US sales ... RedOrbit Merck, Ranbaxy deal could generate $100m - Jun 1, 2008 Currently, Merck has just one anti-fungal drug on the market, Cancidas, yet the company is one of the largest producers of vaccines aimed at preventing ... IndUS Business Journal Merck and Paratek Pharmaceuticals Sign Collaboration Agreement for … - Mar 9, 2006 ...market with CANCIDAS(R), INVANZ(R), and PRIMAXIN(R) and their legacy of innovating and delivering important new therapeutics to the marketplace." ... RedOrbit Article: Echinocandins offer antifungal therapy with low toxicity,... - May 15, 2005 The echinocandin caspofungin (Cancidas) has "no significant interaction" with cytochrome P-450 (CYP450) metabolism or P-glycoprotein, according to product ... Pay-Per-View - Internal Medicine News - HighBeam Research SARAH A. TIEDEMANN JONATHAN D. MASSETT.(CNY) | Article from … - Mar 4, 2007 Massett had packed her husband's $630-per ... exorbitant cost of prescription drugs. Donald Massett needs to take the drug Cancidas for six ... ... Pay-Per-View - Post-Standard - HighBeam Research Indagan venta de medicamentos controlados caducos en farmacias - Oct 28, 2007 También se incautaron cajas de Cancidas, una solución inyectable para pacientes con sida, que tiene un costo de seis mil pesos, pero que se ofertaba en tres ... El Universal - El Universal (México) FDA Approves Expanded Use of Caspofungin Acetate for Paediatric … - Aug 6, 2008 NEW YORK -- August 6, 2008 -- The US Food and Drug Administration (FDA) has approved an expanded label for caspofungin acetate (CANCIDAS), as echinocandin ... DG News Asegura PGR medicamentos caducos - Oct 27, 2007 Entre los medicamentos decomisados para controlar el SIDA se encuentran el Combivir, cuya caja con 60 tabletas tiene un costo de 6 mil pesos; el Cancidas, ... Reforma - Reforma (Suscripción) Incauta PGR medicamentos caducos que se vendÃan en DF - Oct 27, 2007 Otro medicamento caduco para el control de este padecimiento fue el Cancidas, solución inyectable que en el mercado se vende en seis mil pesos, ... El Universal - El Universal (México) Market Commentary on Merck & Co. Inc. - Jun 12, 2007 ...an atherosclerosis product; Primaxin and Cancidas, anti-bacterial/anti-fungal products; Cosopt and Trusopt, the ophthalmological products; Proscar, ... Free with registration - M2 Presswire - AccessMyLibrary.com Amphotericin B the First Antifungal Drug Approved By the US is Still... - Mar 14, 2006 Overall, the antifungal therapeutic market has been stagnating since the introduction of caspofungin (Mercks Cancidas) and voriconazole (Pfizers Vfend), ... RedOrbit Article: New antifungals boast fewer drug interactions.(News) - Skin... - May 1, 2005 The echinocandin caspofungin (Cancidas) has "no significant interaction" with cytochrome P-450 (CYP450) metabolism or P-glycoprotein, according to product ... Pay-Per-View - Skin & Allergy News - HighBeam Research EMEA's PDCO issues PIP review opinions. - Feb 4, 2008 ...the leukotriene receptor antagonist montelukast, marketed as Singulair; and the antifungal agent caspofungin acetate, principal component of Cancidas. ... Free with registration - Pharma Marketletter - AccessMyLibrary.com New drugs could slow rise in fungal infections.(Dermatologic Therapy) - Nov 1, 2006 He noted that he has used caspofungin (Cancidas) quite a bit and has found that it greatly extends Candida coverage. In HIV-positive patients, ... Free with registration - Skin & Allergy News - AccessMyLibrary.com Stocks to watch! - Sep 25, 2006 Pneumovax, a vaccine for the prevention of pneumococcal disease; Recombivax HB, a vaccine for the prevention of hepatitis B; Primaxin and Cancidas, ... Free with registration - M2 Presswire - AccessMyLibrary.com Research and Markets: Examine Financial Performance of Merck & Co … - Oct 9, 2006 Cancidas (caspofungin acetate) is a water-soluble semi-synthetic agent derived from a fermentation product discovered at Merck's laboratories in Madrid. ... Genetic Engineering News - Genetic Engineering News (press release) Research and Markets: Examine Financial Performance of Merck & Co … - Sep 10, 2006 Cancidas (caspofungin acetate) is a water-soluble semi-synthetic agent derived from a fermentation product discovered at Merck's laboratories in Madrid. ... FinanzNachrichten.de Fighting fungal infections: new antifungal therapies may help tame... - Aug 7, 2006 Since the approval of the first echinocandin, caspofungin (Cancidas, Merck), two new drugs available in this class are micafungin (Mycamine, ... Free with registration - Drug Topics - AccessMyLibrary.com Epidemiologically speaking… - Sep 30, 2007 ...owned subsidiary of Merck) that developed Cancidas (caspofungin), and Pfizer, which came up with Vfend (voriconazole) and Eraxis (anidulafungin). ... Express Pharma Current Research on Merck & Co. Inc. - Jun 18, 2007 ...an atherosclerosis product; Primaxin and Cancidas, anti-bacterial/anti-fungal products; Cosopt and Trusopt, the ophthalmological products; Proscar, ... Free with registration - M2 Presswire - AccessMyLibrary.com Incidence of fungal keratitis increases dramatically: wearers of soft... - Nov 1, 2007 New systemic antifungal drugs include voriconazole (Vfend, Pfizer), caspofungin (Cancidas, Merck), micafungin (Mycamine, Astellas), and systemic ... Free with registration - Ophthalmology Times - AccessMyLibrary.com Top stories, Leaders speak, Company News, Sector News, Market talk, … - Sep 20, 2008 The Scientist Award was conferred upon Dr.Meenakshi Sivakumar of Piramal Lifesciences, the Marketing Excellence Award went to MSD for “Cancidasâ€? (new ... India Infoline.com Article: New antifungals boast fewer drug interactions: the echinocand... - May 1, 2005 The echinocandin caspofungin (Cancidas) has "no significant interaction" with cytochrome P-450 (CYP450) metabolism or P-glycoprotein, according to product ... Pay-Per-View - Family Practice News - HighBeam Research DRUGS GIANT MERCK ANNOUNCES RETURN TO INDIA. - Jul 25, 2005 The products include Invanz, a second generation beta-lactam anti-biotic, Cancidas, an anti-fungal and two vaccines, Pneumovax (anti-pneumonia) and Varivax ... $4.95 - AsiaPulse News - ECNext Fungal Infection May Have Killed Ducks | Article from AP Online | … - Dec 15, 2006 The Food and Drug Administration approved Cancidas to treat infections known as invasive aspergillosis in seriously ill patients for whom other therapies ... Pay-Per-View - Associated Press/AP Online - HighBeam Research Press Release: Trius Therapeutics Recruits Merck Executive to Lead … - Jun 4, 2007 Research for Merck, made major contributions to the development and registration of multiple marketed drugs including INVANZ(R), and CANCIDAS(R). ... Pay-Per-View - PR Newswire - HighBeam Research Micafungin approval strengthens antifungal armamentarium.(Infectious ... - May 1, 2005 The echinocandin class also includes caspofungin (Cancidas), approved in 2001. Two more drugs in this class, anidulafungin and aminocandin, ... Pay-Per-View - Family Practice News - HighBeam Research Competitors by Product Report - Aug 9, 2008 Cancidas (Caspofungin Acetate); MK-3281; MK-4965; MK-7009; MK-8122; V419; V502 HPV Vaccine; V512 Influenza Vaccine; V526 HIV Vaccine; V710 S. Aureus Vaccine ... $75.00 - Revere Reports - Revere Investor Focus: Medical Companies On The Move. - Apr 10, 2007 ...an atherosclerosis product; Primaxin and Cancidas, anti-bacterial/anti-fungal products; Cosopt and Trusopt, the ophthalmological products; Proscar, ... $4.95 - M2 Presswire - ECNext FDA Approves First Drug for Carsick Dogs | Article from AP Online | … - Mar 1, 2007 AP Online 01-29-2001 FDA Approves Drug for Deadly Fungus WASHINGTON (AP) -- The government approved a new drug called Cancidas on Monday for immune ... Pay-Per-View - Associated Press/AP Online - HighBeam Research Regan Campbell Ward*McCann: shop sheds med ed, looks to the West … - Jul 1, 2008 Medrageous won work on Merck's antifungal Cancidas. Read all of this article with a FREE trial. COPYRIGHT 2008 Haymarket Media, Inc. This material is ... Pay-Per-View - Medical Marketing & Media - HighBeam Research Patterson Cos Inc acquires Dolphin Imaging Systems LLC - Dec 19, 2008... - Dec 19, 2008 Eraxis Caspofungin Cancidas, Caspo M-Co Micafungin Funguard, Mycamine Pipeline Echinocandins… Pipeline and Commercial Insight: Anxiety Disorders-Viable ... Pay-Per-View - deals - Alacra Store Press Release: Market Commentary on Merck & Co. Inc. - M2 Presswire |... - Jun 28, 2007 ...an atherosclerosis product; Primaxin and Cancidas, anti-bacterial/anti-fungal products; Cosopt and Trusopt, the ophthalmological products; Proscar, ... Pay-Per-View - M2 Presswire - HighBeam Research Competitors by Product Report - Aug 9, 2008 Cancidas (Caspofungin Acetate); MK-0608; MK-7009; MK-8122; V502 HPV Vaccine; V512 Influenza Vaccine; V526 HIV Vaccine; V710 S. Aureus Vaccine ... $75.00 - Revere - Alacra Store Anidulafungin: an echinocandin antifungal for the treatment of... - Aug 1, 2006 ...(10) The approval of anidulafungin makes it the third echinocandin approved by FDA, joining caspofungin (Cancidas, Merck) (2001) and micafungin (Mycamine, ... $4.95 - Formulary - ECNext In- Depth Research on Merck & Co. Inc. - Apr 13, 2007 ...an atherosclerosis product; Primaxin and Cancidas, anti-bacterial/anti-fungal products; Cosopt and Trusopt, the ophthalmological products; Proscar, ... $4.95 - M2 Presswire - ECNext Press Release: Merck & Co., Inc. Announce FDA Approves JANUMET(TM … - Apr 2, 2007 M2 Presswire; January 30, 2009 ; 700+ words ... ... and Trusopt, the ophthalmological products; Primaxin and Cancidas, the anti bacterial/anti fungal ... Pay-Per-View - M2 Presswire - HighBeam Research Top 200 drugs used in hospitals in 2006.(Table) - Apr 16, 2007 Taxotere 286624362.00 4.26 26 Ultane 284418649.68 2.70 27 Cancidas 275150690.26 -0.74 28 Thrombin-JMI 254922999.49 10.24 29 Sodium Chloride 252097230.90 ... $4.95 - Drug Topics - ECNext New antifungal offers another option. - Apr 3, 2006 ...joins both caspofungin (Cancidas, Merck) and micafungin (Mycamine, Astellas Pharma) in the fight against fungal infections in seriously ill patients. ... $9.94 - Drug Topics - Alacra Store Read the factors that are changing the Antifungals Market today... - Jan 25, 2006 Overall, the antifungal therapeutic market has been stagnating since the introduction of caspofungin (Mercks Cancidas) and voriconazole (Pfizers Vfend), ... $4.95 - M2 Presswire - ECNext United States top 200 brand and generic drugs used in hospitals in … - Jun 19, 2006 354711452.46 -7.05 53 Lexapro 337722763.25 27.62 54 Integrilin 334507341.61 -3.26 55 Cancidas 323310648.21 24.84 56 Ultane 316228796.18 15.88 57 Abilify ... $20.00 - Drug Topics - Alacra Store RWS Holdings PLC acquires Eclipse Translations Ltd - Deal Snapshot - ... - Feb 2, 2005 Bronchoalveolar…two pathogens is unlikely to eclipse the markets for currently more…core market, Cancidas, managed to hold onto the lead over its… ... Pay-Per-View - deals - Alacra Store M2 PRESSWIRE-2 October 2006-The Street Review: Investor Alert!(C) … - Oct 2, 2006 ...a vaccine for pneumococcal disease; Recombivax HB, a vaccine for hepatitis B; Primaxin and Cancidas, which are antibacterial/antifungal products; ... $4.95 - M2 Presswire - ECNext Press Release: Current Research on Merck & Co. Inc. - M2 Presswire | ... - Jun 18, 2007 ...an atherosclerosis product; Primaxin and Cancidas, anti-bacterial/anti-fungal products; Cosopt and Trusopt, the ophthalmological products; Proscar, ... Pay-Per-View - M2 Presswire - HighBeam Research Competitors by Product Report - Sep 27, 2008 Cancidas (Caspofungin Acetate); MK-3281; MK-4965; MK-7009; MK-8122; V419; V502 HPV Vaccine; V512 Influenza Vaccine; V526 HIV Vaccine; V710 S. Aureus Vaccine ... $75.00 - Revere Reports - Revere Article: Mycamine joins ranks of approved antifungals.(News) - Skin &... - May 1, 2005 The echinocandin class also includes caspofungin (Cancidas), approved in 2001. Two more drugs in this class, anidulafungin and aminocandin, ... Pay-Per-View - Skin & Allergy News - HighBeam Research Trius Therapeutics Recruits Merck Executive to Lead Drug Development ... - Jun 4, 2007 Research for Merck, made major contributions to the development and registration of multiple marketed drugs including INVANZ(R), and CANCIDAS(R). ... $4.95 - PR Newswire - ECNext Competitors by Product Report - Dec 27, 2008 Cancidas (Caspofungin Acetate); MK-3281; MK-4965; MK-7009; MK-8122; V419; V502 HPV Vaccine; V512 Influenza Vaccine; V526 HIV Vaccine; V710 S. Aureus Vaccine ... $75.00 - Revere Reports - Revere Brand Names/Synonyms: Cancidas is also known by the following brand names and/or synonymsCancidas; Caspofungin; Caspofungin Acetate; M991; MK-0991 Drug Category: Cancidas is categorized under the following by the FDA: Antifungals; Antifungals; ATC:J02AX04 Dosage Forms: POWDER FOR SOLUTION Absorption: 92% tissue distribution within 36-48 hours after IV infusion Interactions: [an error occurred while processing this directive] Chemical IUPAC Name: 1-[(4R,5S)-5-[(2-aminoethyl)amino] -N2-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-[(3R) -3-hydroxy-L-ornithine] pneumocandin B0 |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |